Shortly after General Electric went to its medical care division, the recently launched company began to buy artificial intelligence technology. To share some strategic ideas, IFI digital science claims patent services has taken a look at the patents of the target companies To see what capabilities are bringing the medical technology company.
The “obviously obvious” phrase is used in many contexts, from political exchanges to newspaper opinion article columns. Interestingly, it is rarely used in the field of real patents, but in the case of the General Electric Health Division (GE), its use seems completely appropriate.
In early 2023, GE made the decision to turn the medical care of GE, and immediately after the measure, the new entity began its merger and acquisition strategy by acquiring two own companies: health and imactis. At this early stage, is it possible to infer if they were solid investments? Six months later, there is still a way to go before the financial results of the full year are published along with other financial data. However, the IFI Digital Science Company claims Patent Services, a global provider of patent databases for application developers, data scientists and product managers, can obtain information when investigating the patents that are now possessed of newly expanded ge.
Patent = Strategic Ideas
It must be “obviously obvious”, but the verification of the patents of the companies can be part of any process of due diligence before making an investment decision. This not only helps to understand risk and technology overlays, but can also be used to determine where R&D efforts are currently focused on the acquisition of objectives and, in turn, establishes the strategy for the newly fused entity . Analyze the patent holdings of a company in the middle of the treatment of mergers and acquisitions provides information, such as:
- Strategic direction of companies (that is, as the extent to which they are advancing in AI)
- The unique shots of M&A transactions, as possible, depending on the technologies of the companies, whether or not the basic skills overlap with the acquirer company
- Determine whether the central powers of a company improve or not through the acquisitions that are carried out
The latest IFI acquisition report Take a look at Ge Healthcare’s acquisitions of IMACTIS and Subtitulance Patent Technologies to determine the innovative direction of the company.
‘A good adjustment’
So what ideas can be obtained from patent data about Ge Healthcare and its nascent merger and acquisition strategy? According to the report, the acquisition of subtitles and imactis was a “good adjustment” for Ge Healthcare. Both acquisitions point to the continuous growth of Ge Healthcare in terms of AI and the application of AI to their existing central technologies. Specifically:
- Imaactis is a technological health company that offers, among other things, the provision of 3D virtual images to surgical navigation
- The Health subtitle focuses on providing AI and image generation capabilities to ultrasound technologies
You can see in the table below that Ge Healthcare competes with several important companies in the establishment of AI-related patents, which increased in 2019-2020 before immersing itself in 2021. As such, the acquisitions in early 2023 of the companies that They are focused on technology and AI in particular seem to be a good strategic movement, especially given the rage around AI technology since the late 2022.
What the data says
The report concludes that both health and imactis make sense for GE’s medical care for several reasons. In the current competitive climate, the Health subtitle adds the necessary abilities, while Imaactis adds new dimensions to the set of patents it has with 3D virtual images. In general, it is a gold star for Ge Healthcare when it comes to improving its patent and future commercial strategy. Isn’t that obvious?
Three key conclusions
1. The recently enlarged GE medical care.
2.The latest IFI acquisition report Take a look at the acquisitions of Ge Healthcare of the Patent Technologies of IMACTIS and Subtitulance to determine the innovative direction of the company: the report concludes that both the subtitles and the IMACTIS make sense for Ge Healthcare for several reasons.
3. Checking companies should be part of any due diligence process before any corporate investment decision is made, especially in the pharmaceutical sector.
About the author
Simon LinacreContent Manager, Brand & Press | Digital science
Simon has 20 years of experience in academic communications. He has given conferences and published on the issues of the Bibliometry, the ethics of the publication and the impact of the research, and has recently written a book on predatory publications. Simon is an ALPSP tutor and has also served as COPE trustee.
AI publication: buying or not buying first appeared in digital science.
#buy #buy
